Hair Loss Treatment: An Evidence-Based Review of What Actually Works

Hair loss is one of the most heavily marketed corners of medicine — and one of the most misrepresented. Here is an honest map of every major strategy, ranked by how strong the evidence actually is, for men and for women.

Roughly 50% of men and 40% of women experience pattern hair loss — androgenetic alopecia — over a lifetime. It is not merely cosmetic: for most people it is a slow, progressive miniaturization of the hair follicle driven by genetics and hormones, and, like most chronic processes, it responds best when it is caught early and managed consistently. The problem is not that treatments don’t exist. The problem is that the field is crowded with claims — serums, lasers, “growth” peptides, stem-cell injections, supplement stacks — that range from firmly proven to entirely investigational, all sold with roughly equal confidence. This review walks through every major strategy, links the primary peer-reviewed evidence, and labels each one by how strong that evidence actually is. That honesty is the whole point: the therapies that work are genuinely effective, and separating them from the ones that merely sound effective is exactly what an evidence-based clinic is for.

---

How Pattern Hair Loss Actually Works

In genetically susceptible people, the hormone dihydrotestosterone (DHT) — produced from testosterone by the enzyme 5-alpha-reductase — binds to receptors in scalp follicles and progressively shrinks them. With each growth cycle the follicle produces a finer, shorter, lighter hair, until it stops producing a visible hair at all. This is miniaturization, and it explains the two levers every effective medical therapy pulls: either reduce the hormonal signal that drives miniaturization (the 5-alpha-reductase inhibitors), or extend the growth phase and blood supply of the follicles you still have (minoxidil). It also explains the single most important rule in this field: treatment protects and thickens the hair you still have far more reliably than it regrows what is already gone. Starting early, and staying consistent, is worth more than any individual product.

Female pattern hair loss shares much of this biology but not all of it — women typically show diffuse thinning over the crown rather than a receding hairline, hormones play a more variable role, and, crucially, the treatment hierarchy that works for men does not transfer directly to women (more on that in Section 7). With that framework in place, here is an honest map before we go deeper.

---

The Proven Foundation: FDA-Approved Therapy

Established · approved indications

Topical minoxidil 5%

Minoxidil is the most studied topical hair-loss treatment in the world and is FDA-approved for both men and women. It works by extending the follicle’s growth phase and improving local blood supply. In men, 5% solution produced roughly 45% more regrowth than 2% over 48 weeks, and 5% foam clearly beat placebo. In women, once-daily 5% foam proved non-inferior to twice-daily 2% solution with fewer side effects. One honest caveat: minoxidil is a prodrug that must be activated by an enzyme (sulfotransferase) in the scalp, and people vary in how much of that enzyme they have — which is why some are “non-responders.” (The commercial genetic tests that claim to predict this are not clinically validated.)

Oral finasteride 1 mg (men)

Finasteride blocks the enzyme that converts testosterone to DHT, lowering scalp DHT by roughly 60–70% and attacking the hormonal driver of miniaturization at its source. In the pivotal trials, about 90% of men stabilized or improved, with measurable regrowth sustained over two years. It is the best-studied oral hair drug we have. Two points deserve plain talk: finasteride roughly halves PSA, so men should tell their physician they take it before prostate screening; and while a small percentage of men report sexual side effects (usually reversible on stopping), “post-finasteride syndrome” is a real enough signal to warrant honest, informed consent even though its incidence and causation remain unproven. Both the pro- and anti-finasteride camps tend to overstate their case — the evidence-based position sits in between.

Combination: minoxidil + finasteride

Because the two drugs work through completely different mechanisms, using them together outperforms either alone. A 2025 meta-analysis of seven randomized trials found the combination added roughly +9 hairs/cm² over minoxidil by itself, with about three times the odds of marked improvement. The benefit is real, if modest in absolute terms — and for many men, the combination is the preferred backbone of a serious plan.

---

Advanced & Off-Label Prescriptions

Strong & emerging · off-label

Oral dutasteride 0.5 mg

Dutasteride blocks both types of 5-alpha-reductase (finasteride blocks mainly one), suppressing DHT by more than 90%. Across the major network meta-analyses it ranks as the single most effective medication for male pattern hair loss, beating finasteride by roughly +7 hairs/cm². It is FDA-approved for prostate enlargement and used off-label for hair (it is formally approved for hair loss in South Korea and Japan). Its long duration of action is a genuine consideration — a reason it warrants physician oversight, particularly in younger men thinking about fertility.

Low-dose oral minoxidil (1.25–5 mg)

The biggest recent shift in practice is taking minoxidil as a low-dose pill rather than a topical. It is convenient and effective — but the evidence is often misread. In a head-to-head randomized trial, oral 5 mg did not statistically beat topical 5% for most measures over 24 weeks, and unwanted body-hair growth (hypertrichosis) was far more common on the pill. The fair conclusion: low-dose oral minoxidil is an excellent option when topicals are impractical or poorly tolerated — not a proven upgrade in raw efficacy — and the low dose is used specifically to limit cardiovascular effects, which is one more reason it belongs under medical supervision.

Topical finasteride / dutasteride — and an important FDA warning

Applying a 5-alpha-reductase inhibitor to the scalp can lower DHT locally while reducing — though not eliminating — systemic exposure; a phase III trial of topical finasteride showed meaningful regrowth with about a third less drop in blood DHT than the oral form. That is a promising idea. But patients should know that as of an April 2025 FDA alert, there is no FDA-approved topical finasteride product, the popular compounded telehealth sprays are unevaluated for safety and consistency, and the FDA logged 32 adverse-event reports (including sexual and neuropsychiatric effects, some persistent) tied to these compounded products. This is one of the clearest examples in the whole field of marketing running ahead of regulatory evidence — a good reason to have a physician, not a website, decide whether it belongs in your plan.

---

In-Office Procedures

Emerging · adjunctive

Microneedling

Creating controlled micro-injuries in the scalp triggers wound-healing and growth signals and, importantly, helps topical drugs penetrate. In a randomized trial, microneedling plus minoxidil dramatically outperformed minoxidil alone (a hair-count change of about 91 versus 22), and a second trial confirmed statistical superiority. It is one of the better-supported procedures — but the evidence is for microneedling as an add-on to medical therapy, not a standalone cure.

Platelet-rich plasma (PRP)

PRP concentrates growth factors from your own blood and injects them into the scalp. Meta-analyses lean positive — adding roughly +9 hairs per measured area when combined with minoxidil — but this is also the therapy where clinic marketing most outruns the data: protocols (spin speed, platelet concentration, activation, session number) vary enormously and strongly affect results. Honestly framed, PRP is promising and protocol-dependent, not a sure thing, and it works best as part of a combination plan.

Low-level laser therapy (LLLT) & ketoconazole shampoo

LLLT caps and combs are FDA-cleared (a substantial-equivalence bar, not the same as drug “approval”) and a meta-analysis of double-blind trials shows a real but modest benefit — a reasonable adjunct if you’ll use it consistently, not a primary therapy. Note the language: cosmetic “red-light” wellness marketing routinely blurs “cleared” into “proven.” Finally, ketoconazole 2% shampoo has mild anti-androgen and anti-inflammatory effects on the scalp; the evidence is limited but supportive, and it’s a low-cost, low-risk add-on — not a standalone treatment.

---

Nutrition & Supplements

Selective · correct deficiencies

The single most defensible nutritional intervention is correcting a documented deficiency — not supplementing people who are already replete. Women with hair loss consistently show lower iron stores (ferritin) and higher rates of vitamin D deficiency, and low zinc shows up especially in certain shedding disorders. Checking and correcting ferritin, vitamin D, and zinc (and thyroid) is real medicine; taking them blindly is not. Saw palmetto is a weak natural 5-alpha-reductase inhibitor with only low-quality supporting evidence — far weaker than finasteride, not a substitute for it.

Marine-protein nutraceuticals (the Viviscal/Nutrafol category) do have positive randomized trials — but they are small and largely funded by the manufacturers, so they warrant cautious optimism rather than confident claims. And a specific safety point on biotin: it helps hair only in the rare case of true deficiency, and importantly, the FDA warns that biotin supplements can cause falsely abnormal lab results — including falsely low troponin, which can mask a heart attack — so patients should stop biotin before bloodwork. This is exactly the kind of detail a supervising physician catches and a supplement label does not.

---

The Regenerative Frontier: Exosomes, Stem Cells & Peptides

Investigational · not FDA-approved

This is the most heavily promoted and least proven corner of hair restoration, so it deserves the clearest possible statement: there are currently no FDA-approved exosome, stem-cell, or peptide products for hair loss. Clinics offering them are, in regulatory terms, marketing unapproved biologics.

Exosomes — tiny signaling packets derived from stem cells, microneedled or injected into the scalp — are mechanistically fascinating, but the human evidence is thin: a systematic review of 16 studies included only a single small clinical trial. More to the point, the FDA issued a public safety notification in December 2019 after serious adverse events from unapproved exosome products, warning that clinics were “deceiving patients with unsubstantiated claims.” Stem-cell–based approaches (including adipose-derived conditioned media) rest almost entirely on small, uncontrolled case series — encouraging signals, but not proof.

Growth peptides — copper peptides such as GHK-Cu, and Wnt-pathway peptides like PTD-DBM — are a good illustration of the gap between mechanism and evidence. The biology is real and interesting: GHK-Cu influences signaling that matters to the follicle, and Wnt-targeting peptides regrow hair impressively… in mice. But the human data are essentially cosmetic-grade — small, old, without large randomized trials — and, critically, these peptides do not block DHT, so they cannot replace proven therapy. We include them not to dismiss the science, which is legitimately promising, but to be honest that the marketing is years ahead of the evidence. When and if better trials arrive, our position will move with them — that is what evidence-based means.

---

Hair Loss in Women: A Different Playbook

Distinct evidence base

Female pattern hair loss deserves its own section because treating women as “men with less data” is a common and consequential mistake. The first-line, and only FDA-approved, medication for women is topical minoxidil (2% solution or once-daily 5% foam), with a Cochrane review of 22 trials confirming benefit. Beyond that, the evidence diverges sharply from the male playbook.

Spironolactone, an oral anti-androgen used off-label, showed greater terminal-hair regrowth than placebo in the first placebo-controlled pilot trial — but with meaningful menstrual side effects, and it is teratogenic, so it requires reliable contraception. Low-dose oral minoxidil is increasingly used in women at lower doses (0.25–2.5 mg) with promising results. Critically, finasteride and dutasteride are not FDA-approved in women, are teratogenic, and the cleanest trial in postmenopausal women was negative — they are defensible only in specific cases of demonstrable hyperandrogenism, and on weaker evidence. The male “dutasteride > finasteride > minoxidil” ranking simply does not apply to women, which is why female hair loss is a case for individualized, physician-guided evaluation — including a workup for iron, thyroid, and hormonal contributors — rather than an off-the-shelf protocol.

---

The Long View

A booming industry, a thin evidence base, and the case for a guide

Hair loss has become one of the fastest-growing categories in consumer health — a multibillion-dollar market propelled by telehealth, direct-to-consumer subscriptions, and a wave of “wellness” branding that has learned to make an unproven serum and a rigorously tested drug look identical on a checkout page. The tailwind is real: the same enthusiasm that made GLP-1 medications a cultural phenomenon has spilled into every adjacent category, peptides and regenerative injectables included. Demand is surging faster than evidence, and a great deal of what is sold — compounded sprays, exosome injections, “growth” peptide kits, laser gadgets, supplement stacks — is marketed with a confidence the underlying data simply do not support.

The regulatory reality is worth understanding, because the marketing depends on you not understanding it. “FDA-approved” means a product was tested and cleared for a specific use. “FDA-cleared” (many laser devices) is a lower bar. “Compounded” means a pharmacy prepared it for you — it is not FDA-approved, and its quality depends entirely on the pharmacy. And gray-market peptides sold online as “research use only” are a legal fiction: unapproved, unmonitored, and sometimes contaminated. The FTC’s own standard for a health claim is “competent and reliable scientific evidence” — ideally randomized, controlled human trials — a bar most of the loudest hair products never clear. None of this makes the frontier worthless. It makes it unsorted.

That is the entire argument for an evidence-based physician, and it is not a marketing line — it is a function. A physician tells you which tier a therapy actually occupies, starts with what is proven, adds the promising as a considered adjunct, and refuses to sell you the investigational as if it were settled. A physician checks the ferritin and thyroid that a supplement label ignores, adjusts your PSA for the finasteride you’re taking, catches the biotin that could distort your cardiac labs, and matches the plan to your biology — male or female, early or advanced. Used this way, these tools are genuinely powerful: pattern hair loss is one of the most treatable chronic conditions in medicine when it is caught early and managed consistently, and preserving your own hair is preventive medicine in the most literal sense.

So where does that leave a thoughtful patient? Not cynical, and not credulous. The therapies that work are legitimately effective; the frontier is legitimately exciting; and the difference between a result and a regret is almost always whether someone with medical judgment — not an algorithm optimizing for a subscription — decided what belonged in your plan. That is the whole project: not the average promise, but the intervention that actually fits you.

---

If You’re Considering Treatment